Health Care & Life Sciences » Biotechnology | Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
52,625.40
93,620.00
162,990.00
104,765.90
127,425.40
81,232.50
Total Accounts Receivable
3,301.60
2,804.20
7,333.10
16,569.90
6,489.80
4,054.90
Other Current Assets
2,756.60
2,522.90
1,527.90
3,261.50
4,446.90
2,527.40
Total Current Assets
58,683.60
98,947.10
171,850.90
124,597.20
138,362.20
87,814.80
Net Property, Plant & Equipment
2,886.50
4,583.20
7,306.70
9,025.40
18,320.20
15,949
Total Investments and Advances
10,482.80
12,890.80
19,993.20
19,829.60
11,394.50
9,405.90
Intangible Assets
15,832.10
14,889.40
14,019.20
18,141.80
16,523.10
15,273.50
Other Assets
402.10
474.60
670.80
2,113.20
2,639.40
2,670
Total Assets
88,287.20
131,785.10
213,840.90
173,707.20
187,239.30
131,113.30
Accounts Payable
2,388.00
2,031.50
4,457.40
6,993.20
8,491.80
Other Current Liabilities
26,578.50
11,992.30
27,009.00
36,829.80
26,913.70
Total Current Liabilities
28,966.50
14,023.80
31,466.40
43,823.00
35,405.40
Deferred Taxes
195.80
504.00
175.60
174.80
24.80
Other Liabilities
6,222.30
5,719.70
6,265.80
6,330.90
9,320.30
Total Liabilities
35,384.50
20,247.50
37,907.80
50,328.70
44,750.50
Common Equity (Total)
52,455.00
111,227.00
175,687.20
123,282.20
142,392.50
Total Shareholders' Equity
52,455.00
111,227.00
175,687.20
123,282.20
142,392.50
Total Equity
52,902.70
111,537.60
175,933.10
123,378.40
142,488.80
Liabilities & Shareholders' Equity
88,287.20
131,785.10
213,840.90
173,707.20
187,239.30
Accumulated Minority Interest
447.70
310.60
245.80
96.30
96.30

About Inovio Pharmaceuticals

View Profile
Address
660 West Germantown Pike
Plymouth Meeting Pennsylvania 19462
United States
Employees -
Website http://www.inovio.com
Updated 07/08/2019
Inovio Pharmaceuticals, Inc. engages in the development of active DNA immunotherapies for cancer and infectious diseases. Its portfolio of immune therapies includes SynCon immunotherapies and electroporation delivery systems. The company was founded on June 29, 1983 and is headquartered in Plymouth Meeting, PA.